Report : MEA Respiratory Tract Infection Treatment Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug (Antibiotics, NSAIDs, Cough Suppressants, Nasal Decongestants, and Others), Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), Route of Administration (Oral and Parenteral), Age Group (Pediatric and Adult), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and Country
According to our new research study on "MEA Respiratory Tract Infection Treatment Market Size and Forecast to 2031 - Country Analysis - by Drugs, Disease Indication, ROA, Age Group, and Distribution Channel," the market is expected to grow from US$ 2.09 billion in 2023 to US$ 2.97 billion by 2031; it is estimated to record a CAGR of 4.50% during 20222023-20310.
Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. Though most RTIs resolve on their own, occasionally, a visit to your doctor may be necessary. The MEA respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players. Key factors driving the market growth include the rising cases of respiratory infections in the Middle East, and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders market growth. Further, the advent of antiviral treatment for MERS is expected to bring new MEA respiratory tract infection treatment market trends in the coming years.
The Middle East has been experiencing a rise in cases of respiratory infections, mainly driven by factors such as air pollution, smoking prevalence, crowded living conditions, and seasonal viral outbreaks. According to the NCBI data published in 2019, acute lower respiratory tract infections are a serious health issue that impacts nearly 15% of the Saudi population annually. Epidemiological research carried out during the past three decades suggests that most of these diseases are caused by viruses. As per the Saudi German Hospitals Group UAE, ~13% of adults and 20% of children in Dubai suffer from asthma, making it a serious health concern. Variables such as lifestyle decisions, genetic predisposition, and environmental triggers can be related to such a high incidence of asthma. The increasing burden of respiratory tract infections has created a demand for effective treatment options. Pharmaceutical companies capitalize on such growing needs by developing and offering innovative therapies. Moreover, with a focus on research and development, public-private partnerships, and awareness initiatives, they can play a crucial role in addressing challenges posed by respiratory infections in the Middle East. Zoetis, Inc., Secure Diagnostics, Thermo Fisher Scientific, Inbios India, Ubio Bitechnology Systems, Gold Standerd Diagnostics, VMRD Inc., Fujifilm, Randox Laboratories Ltd, and Idexx Laboratories are among the leading companies operating in the MEA respiratory tract infection treatment market.
The report segments the MEA respiratory tract infection treatment market as follows:
In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023-2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.
Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023The lower respiratory tract infection segment held a larger market share in 2023 based on disease indication. It is further anticipated to register a higher CAGRhat a higher CAGR will be registered from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.
By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023-2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.
In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023-2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.
In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023-2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.
MEA Respiratory Tract Infection Treatment Market: Competitive Landscape and Key Developments
Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Orion Corporation, and Julphar are among the prominent players profiled in the MEA respiratory tract infection treatment market report. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com